65th ASH Annual Meeting & Exposition: 703. Cellular Immunotherapies: Basic and Translational: Novel Approaches for Next Generation Cellular Immunotherapies

Symposia: Cellular Immunotherapies: Basic and Translational Oral and Poster Abstracts
Oral

Research, Bleeding and Clotting, Acute Myeloid Malignancies, AML, Translational Research, hemophilia, Plasma Cell Disorders, Diseases, Therapies, immunology, Lymphoid Malignancies, Myeloid Malignancies, Biological Processes

Room 6A (San Diego Convention Center)

Moderators:

Alvaro Urbano-Ispizua Sr., MD, Department of Hematology, Hospital Clínic, Barcelona and Sarwish Rafiq, PhD, Emory University

Disclosures:

No relevant conflicts of interest to declare.

9:30 AM

463

Development of an Ex Vivo Precision Gene Engineered B Cell Medicine That Produces Active and Sustained Levels of FIX for the Treatment of Hemophilia B

Hanlan Liu¹^*, Swati Singh¹^*, Timothy Mullen, PhD¹^*, Caroline Bullock¹^*, Sean Keegan¹^*, Troy Patterson¹^*, Amy Lundberg¹^*, Sakshisingh Thakur¹^*, Charuta Yadav¹^*, Shamael Dastagir¹^*, Lily Li¹^*, Wayne Bainter¹^*, Shalini Chilakala¹^*, Anja Hohmann, PhD¹^*, Adam Lazorchak, PhD¹^* and Richard A Morgan, PhD²

¹Be Biopharma, Cambridge, MA
²Be Biopharma, Center Harbor, NH

9:45 AM

464

Human iPSC-Derived NK Cells with Knock-in of the BCL2 G101V Mutation Are Resistant to Venetoclax and Demonstrate Improved Anti-AML Activity In Vivo

Benjamin Goldenson, MD, PhD¹, Davide Bernareggi²^*, Jiyoung Yun, M.S.³^*, Samuel Shia⁴^* and Dan S Kaufman, MD, PhD⁴

¹Department of Medicine, Division of Regenerative Medicine, University of California San Diego, La Jolla, CA
²UCSD, La Jolla
³University of British Columbia, Vancouver, BC, Canada
⁴University of California San Diego, La Jolla, CA

10:00 AM

465

Discovery and Development of CD70 As a Cellular Therapy Target in High Risk Multiple Myeloma

Corynn Kasap, MD, PhD¹, Adila Izgutdina, MD²^*, Bonell Patino Escobar, MD²^*, Yu-Hsiu Tony Lin, BA²^*, Huimin Geng, PhD³^*, Gianina Wicaksono, BA²^*, Daphne Dupere-Richer, PhD⁴^*, Emilio Ramos, MD, PhD³, Abhilash Barpanda, PhD²^*, Anjanaa Vijayanarayanan, MD²^*, Fernando Salangsang⁵^*, Paul Phojanakong, BA⁵^*, Juan Antonio Camara Serrano, PhD⁵^*, Veronica Steri, PhD⁵^*, William Karlon, MD, PhD²^*, Mala Shanmugam⁶, Lawrence H. Boise⁷, Benjamin G. Barwick⁶, Jonathan D. Licht, MD⁴ and Arun P Wiita, MD, PhD²

¹Department of Medicine, Division of Hematology Oncology, University of California San Francisco, San Francisco, CA
²Department of Laboratory Medicine, UCSF, San Francisco, CA
³Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA
⁴University of Florida, Gainesville, FL
⁵Preclinical Therapeutics Core, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA
⁶Department of Hematology and Medical Oncology, Winship Cancer Institute, School of Medicine, Emory University, Atlanta, GA
⁷Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA

10:15 AM

466

WU-NK-101 (W-NK), a Memory-like (ML) NK Cell, Intrinsically Overcomes Factors Restricting Adoptive Cell Therapy (ACT) in Acute Myeloid Leukemia (AML)

Sergio Rutella, MD, PhD, FRCPath¹, John Muth, MSc²^*, Jayakumar Vadakekolathu, PhD¹^*, Tom Leedom³^*, Alex Hamil³^*, Laura Arthur, PhD⁴^*, Nitin Mahajan, PhD, MSc, MS⁵^*, Elizabeth Schramm, PhD⁶^*, Renaud Warin, PhD⁷^*, Amber M Foust, MS⁸^*, David Boocock, PhD⁹^*, Clare Coveney, PhD⁹^*, Jan Baughman, MPH¹⁰^*, Vincent Petit¹¹^*, Nupur Bhatnagar¹²^*, Kristann Magee⁶^*, Melissa M Berrien-Elliott, PhD¹³^*, Matthew L. Cooper, PhD¹⁴, Jan Davidson-Moncada, MD, PhD, MSc¹⁵ and Todd A Fehniger, MD, PhD¹⁶

¹John van Geest Cancer Research Centre, Nottingham Trent University, Nottingham, United Kingdom
²Wugen, St. Louis, MO
³Wugen, San Diego
⁴Wugen, Saint Louis, MO
⁵Wugen, St Louis, MO
⁶Wugen, St Louis
⁷Carolina BioOncology, Huntersville
⁸Carolina BioOncology, Hunterville
⁹Nottingham Trent University, Nottingham, ENG, United Kingdom
¹⁰Alviso Clinical Research, San Francisco, CA
¹¹Metafora Biosystems, Paris, France
¹²Institut Pasteur, Paris, France
¹³Washington University School of Medicine in St. Louis, St Louis, MO
¹⁴Wugen Inc., Saint Louis, MO
¹⁵Wugen, Washington, DC
¹⁶Washington University School of Medicine in St. Louis, Saint Louis, MO

10:30 AM

467

Engineered Natural Killer Cells Expressing Chimeric Ilt Receptors (CIR) Effectively Target HLA-G Positive AML Tumor Cells

Mylinh Duong, PhD^*, Jihyun Park, PhD^*, Raphael Ognar, MSc, MBA, Simon Wain-Hobson, DPhil^* and Henri Bayle, PhD

NKILT Therapeutics, Houston, TX

10:45 AM

468

Restoration of LAT Signaling in CD33-Directed CAR T Cells Improves Potency and Persistence Against Acute Myeloid Leukemia

Catherine Danis, PhD¹, Lillie Leach¹^*, Amanda Novak²^* and M. Eric Kohler, MD, PhD³

¹University of Colorado, Anschutz Medical Campus, Aurora, CO
²University of Colorado, Anschutz Medical Campus, Aurora
³Department of Pediatrics- Hematology, Oncology, and Bone Marrow Transplant, University of Colorado School of Medicine, Aurora, CO

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

703.O3.6 703. Cellular Immunotherapies: Basic and Translational: Novel Approaches for Next Generation Cellular Immunotherapies